14 Jan 2020
First-in-man randomised comparison of the Angiolite durable fluoroacrylate polymer-based sirolimus-eluting stent vs a durable fluoropolymer-based everolimus-eluting stent in patients with CAD: the ANGIOLITE trial
EuroIntervention Journal
The durable fluoroacrylate polymer-based sirolimus-eluting stent (Angiolite SES) has shown promising preclinical and clinical results regarding inflammatory vascular reaction and neointimal healing. J. Moreu, et al. aimed to compare performance between the Angiolite SES and an everolimus-eluting stent (EES) in patients with coronary artery disease.
The ANGIOLITE trial, a prospective, randomised, multicentre trial, compared the restenosis parameters of both stents in de novo coronary lesions. The primary endpoint was late lumen loss at six-month angiographic follow-up. In-stent healing was assessed by optical coherence tomography (OCT). The main clinical endpoint was target lesion failure (TLF) evaluated up to 24 months. A total of 223 patients were randomised 1:1 to EES or SES. At six months, in-stent late lumen loss was 0.08 mm (±0.38) for EES vs 0.04 mm (±0.39) for SES (difference=–0.04 mm, 95% CI: –0.15, 0.07, p for non-inferiority=0.002).
Authors
J. Moreu, R. Moreno-Gómez, A. Pérez de Prado, B. García del Blanco, R. Trillo, E. Pinar, E. Molina, J. Zueco, A. Merchán, J. Francisco Díaz-Fernández, I. Amat
